Janux Therapeutics
Presence
Janux Therapeutics is one of the...
Janux Therapeutics is a company listed under the stock ticker JANX (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Janux Therapeutics
- David Campbell, Director, President and Chief Executive Officer
- Winston Kung, Director
- Sheila Gujrathi, Director
Popular executive movements at Janux Therapeutics
- Tommy Diraimondo, who was Executive Director, R&D, is promoted to Chief Scientific Officer (posted on January 9 2024).
Create your alert
to follow the executive moves at Janux Therapeutics.
Biotechnology
Janux Therapeutics has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Janux Therapeutics
- Janux Therapeutics Announces Proposed Public Offering of Common Stock
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
- Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
- Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
- Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
- Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
- View more press releases Close
Social media about Janux Therapeutics
- Janux Therapeutics on Wikipedia, Google News & Yahoo Finance
- Janux Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including David Campbell 
Call Janux Therapeutics at +1 858...
